Vinson & Elkins advised Reata Pharmaceuticals Inc. (“Reata”), a global biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases, in its entry into a definitive agreement under which Biogen Inc. has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.
The Vinson & Elkins team was led by partners Lande Spottswood, Robert Kimball and Katherine Frank and senior associate Sang Lee, with assistance from senior associate Grace-Ann Duquette and associates Luke Strieber, Jack Peterson, Nina Ramachandran, Katherine Harclerode and Patience Li. Other key team members were partners David Peck and Brian Russell, counsel Peter Rogers and associate Maddie Brown; partner Shane Tucker, counsel Missy Spohn and Kat Mull and associates Matt Green and Kenneth Strain; partner Sean Becker and associate Andrew Cox; partners Kara Kuritz and Hill Wellford, senior associate Ryan Will and associate Alex Rant; partner Rick Sofield; counsel Brian Howard; counsel Elizabeth McIntyre; counsel Rajesh Patel and associate Warner Scott; and partner Sarah Mitchell.
